



## **Telix Selects Seibersdorf Laboratories to Manufacture Glioblastoma Program**

Melbourne (Australia) and Seibersdorf (Austria) – *17 October 2018*. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has entered into a commercial manufacturing agreement with Seibersdorf Labor GmbH (“Seibersdorf”).

Telix has been working with Seibersdorf under a technology transfer and research agreement for the past year, during which the parties have implemented and validated the use of an automated production system for the manufacture of <sup>131</sup>I-IPA (TLX101). TLX101 is the Company’s therapeutic drug candidate for the treatment of glioblastoma, an aggressive form of brain cancer. Optimization of the manufacturing process has resulted in commercially viable radiochemical yields and a product shelf-life exceeding 100 hours, suitable for centralized manufacturing and global distribution of product for both Telix-run trials and compassionate use.

Telix EU President Odile Jaume stated, “Seibersdorf Laboratories is an immensely capable organization with an excellent technical team. It has been a pleasure to work with them over the past months to develop the manufacturing platform for Telix’s glioblastoma therapeutics program to the stage where we have GMP drug product suitable for trials in Europe and beyond.”

Head of the Radiopharmaceuticals Business Unit at Seibersdorf, Dr Roland Müller, commented, “The TLX101 program is an exciting opportunity for our organization and we are pleased to be working with Telix to deliver this drug product for both clinical trials and potentially commercial use.”

### **About Telix Pharmaceuticals**

Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit [www.telixpharma.com](http://www.telixpharma.com).

### **About Seibersdorf Laboratories**

Seibersdorf Labor GmbH is an Austrian company specialized in high quality laboratory and analysis work, application-oriented research and development as well as consulting and training.

The teams of Seibersdorf Laboratories are service, know-how and technology provider and cover a broad area of scientific expertise: development, production and quality control of radiopharmaceuticals, anti-doping and forensic analysis, radiation protection, ionizing and non-ionizing radiation, radio frequency engineering and electromagnetic compatibility.

The experts of Seibersdorf Laboratories represent Austria on various international committees.

For more information, visit: [www.seibersdorf-laboratories.at](http://www.seibersdorf-laboratories.at)

---